P0592 Safety of the Adjuvant Recombinant Herpes Zoster Vaccine in Crohn’s Disease and Ulcerative Colitis: A Real-World Study
Authors: Kim D H , Park Y H , Kang S B , Kim K O , Park S H , Lee Y J , Lee J , Moon W , Park S J , Na S Y , Kim E S , Oh S J , Shin S Y ,   IBD research group of KASID (Korean Association for the Study of Intestinal Diseases)
Published: January 2025

Abstract

Background
The incidence of inflammatory bowel disease (IBD) is increasing, and herpes zoster (HZ) occurrence in IBD patients, particularly those on immunosuppressive drugs, is a growing concern. The herpes zoster adjuvant recombinant vaccine (Shingrix) may provide a safer alternative to live vaccines, but real-world data on its safety in IBD patients is limited.

Methods
This multicenter prospective observational study is being conducted from August 2023 to July 2025. Patients diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC) who receive the herpes zoster subunit vaccine will be followed for 30 days post-vaccination to assess adverse events (AE) and vaccine safety.

Results
A total of 244 patients were enrolled in the study, consisting of 141 with ulcerative colitis (UC) and 103 with Crohn’s disease (CD). The mean age of the cohort was 45.3 years, with UC patients being older on average (49.7 years) than CD patients (39.3 years, p&lt;0.01). After the first dose, injection site pain was the most commonly reported local adverse event, occurring in 51.2% of patients (UC: 49.6%, CD: 53.4%; p=0.56). Other local adverse events, such as redness (2.0%) and swelling (1.2%), showed no significant differences between UC and CD groups (p&gt;0.05).
Systemic adverse events following the first dose included fatigue (19.3%), myalgia (34.0%), headache (16.0%), shivering (11.5%), fever (11.5%), and gastrointestinal symptoms (6.6%). There were no significant differences between UC and CD patients for these events (p&gt;0.05). Rare severe adverse events were noted, including one case of a disease flare requiring hospitalization in a CD patient post-vaccination (0.4%). Additional events classified as 'others' included itching, Bell’s palsy, and dizziness, with no significant group differences.
For the second dose, 132 patients (UC: 78, CD: 54) were followed. Local adverse events included injection site pain reported by 53.8% of patients (UC: 48.7%, CD: 61.1%; p=0.16). Systemic adverse events, such as fatigue (25.8%), myalgia (35.6%), and headache (15.9%), were similarly reported without significant differences between UC and CD groups (p&gt;0.05). Severe adverse events were not observed after the second dose. Other non-severe adverse events reported included sore throat, nausea, and rash, with no group-specific statistical significance.

Conclusion
The herpes zoster adjuvant recombinant vaccine appears to be safe for use in IBD patients, with no significant differences in adverse events between UC and CD groups. This study suggests that the adjuvant vaccine is a viable alternative to live attenuated vaccines, especially in patients receiving immunosuppressive therapy. Further studies are warranted to confirm its long-term safety and efficacy in this population.

References
1.Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640.
2.Cohen JI. Clinical practice: Herpes zoster. N Engl J Med 2013;369:255-263.
3.Marra F, Parhar K, Huang B, Vadlamudi N. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis 2020;7:ofaa005.
4.Imafuku S, Dormal G, Got Y, Jégou C, Rosillon D, Matsuki T. Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. J Dermatol 2020;47:236-244.
5.Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1483-1490.
6.Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res 2023;21:88-99.
7.Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37.
8.Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis 2021;224:S429-s442.
9.Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010;51:197-213.
10.James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Ann Pharmacother 2018;52:673-680.
11.Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349.
12.Khan N, Patel D, Trivedi C, et al. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2018;16:1919-1927.e1913.
13.Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection 2014;42:325-334.
14.Yun H, Yang S, Chen L, et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol 2016;68:2328-2337.
15.Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci 2014;29:1706-1710.